Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.
Subscribe to ACCEL Lite
Other ACC resources on DAPT and bleeding risk:
1. One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT
2. Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention
3. ACC.24 Presentation Slides | ULTIMATE-DAPT
View all episodes
By American College of Cardiology
3.8
5454 ratings
Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.
Subscribe to ACCEL Lite
Other ACC resources on DAPT and bleeding risk:
1. One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT
2. Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention
3. ACC.24 Presentation Slides | ULTIMATE-DAPT
136 Listeners
320 Listeners
497 Listeners
168 Listeners
881 Listeners
291 Listeners
136 Listeners
1,146 Listeners
39 Listeners
193 Listeners
92 Listeners
368 Listeners
426 Listeners
374 Listeners
36 Listeners